BIONET Corp. (TPEX:1784)
59.30
-0.40 (-0.67%)
Aug 19, 2026, 10:14 AM CST
BIONET Revenue
BIONET had revenue of 338.35M TWD in the quarter ending June 30, 2026, with 11.15% growth. This brings the company's revenue in the last twelve months to 1.29B, up 5.41% year-over-year. In the year 2025, BIONET had annual revenue of 1.24B with 1.19% growth.
Revenue (ttm)
1.29B
Revenue Growth
+5.41%
P/S Ratio
2.32
Revenue / Employee
n/a
Employees
n/a
Market Cap
3.00B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.24B | 14.57M | 1.19% |
| Dec 31, 2024 | 1.22B | 94.73M | 8.40% |
| Dec 31, 2023 | 1.13B | 146.93M | 14.99% |
| Dec 31, 2022 | 980.38M | 58.96M | 6.40% |
| Dec 31, 2021 | 921.42M | 114.85M | 14.24% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| DIVA Laboratories | 894.67M |
| Genetics Generation Advancement | 614.42M |
| Kim Forest Enterprise | 599.63M |
| Welgene Biotech | 398.92M |
| Sofiva Genomics | 379.21M |
| Pharmigene | 187.88M |
| Puriblood Medical | 80.54M |